Phase 1, Two-part (Dose Escalation, Dose Expansion), Multicenter, Non-randomized, Open-label, Multiple Dose, First-in-human Study of CA102N Monotherapy and of CA102N Combined With Trifluridine/Tipiracil (LONSURF) in Subjects With Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 27 Jun 2019
Price : $35 *
At a glance
- Drugs CA 102 N (Primary) ; Tipiracil/trifluridine (Primary)
- Indications Colorectal cancer; Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Holy Stone Healthcare
- 25 Jun 2019 Planned End Date changed from 1 Jun 2021 to 1 Feb 2022.
- 25 Jun 2019 Planned primary completion date changed from 1 Feb 2021 to 1 Sep 2021.
- 25 Jun 2019 Status changed from not yet recruiting to recruiting.